RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
This Quarter Return
+4%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$7.22B
AUM Growth
+$986M
(+16%)
Cap. Flow
+$1.18B
Cap. Flow
% of AUM
16.39%
Top 10 Holdings %
Top 10 Hldgs %
44.55%
Holding
109
New
17
Increased
12
Reduced
6
Closed
14
Top Buys
| 1 |
CLYM
Climb Bio, Inc. Common Stock
CLYM
|
$236M |
| 2 |
Invivyd
IVVD
|
$226M |
| 3 |
Cytek Biosciences
CTKB
|
$206M |
| 4 |
ICVX
Icosavax, Inc. Common Stock
ICVX
|
$171M |
| 5 |
DICE
DICE Therapeutics, Inc. Common Stock
DICE
|
$171M |
Top Sells
| 1 |
Axsome Therapeutics
AXSM
|
$112M |
| 2 |
Novavax
NVAX
|
$95.8M |
| 3 |
Curis
CRIS
|
$57.6M |
| 4 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
$56.4M |
| 5 |
CCXI
ChemoCentryx, Inc.
CCXI
|
$56.1M |
Sector Composition
| 1 | Healthcare | 99.06% |
| 2 | Financials | 0.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
INZY
101
DELISTED
Inozyme Pharma
INZY
| – | – |
-2,003,653
| Closed | -$34.1M |
|
102
Legend Biotech
LEGN
$6.64B
| – | – |
-977,503
| Closed | -$40.1M |
|
103
Intellia Therapeutics
NTLA
$1.26B
| – | – |
-15,000
| Closed | -$2.43M |
|
104
Oric Pharmaceuticals
ORIC
$1.03B
| – | – |
-584,000
| Closed | -$10.3M |
|
105
TherapeuticsMD
TXMD
$12.8M
| – | – |
-156,250
| Closed | -$9.3M |
|
|
CERE
106
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| – | – |
-2,200,000
| Closed | -$56.4M |
|
|
ARYD
107
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
| – | – |
-1,000,000
| Closed | -$10.7M |
|
|
TRIL
108
DELISTED
Trillium Therapeutics Inc.
TRIL
| – | – |
-5,290,481
| Closed | -$51.3M |
|
|
CEREW
109
DELISTED
Cerevel Therapeutics Holdings, Inc. Warrant
CEREW
| – | – |
-233,333
| Closed | -$3.36M |
|